Want to see CH:BANB full AI Analyst Report?
Top Page
Bachem Holding AG
(BANB)
Select Model
Select Model
Rating:67Neutral
Price Target:
CHF84.00
▲(11.93% Upside)
Action:Downgraded
Date:07/22/26
The score is anchored by strong financial quality—especially the conservatively financed balance sheet and solid profitability—tempered by persistent negative free cash flow and uneven cash conversion. Technically, the stock remains in a broader uptrend (above major moving averages) but with weak near-term momentum. Valuation is the main headwind, with a high P/E and only a modest dividend yield.
Positive Factors
Conservatively financed balance sheet
Extremely low leverage and a growing equity base provide durable financial resilience. Low debt reduces interest burden, preserves borrowing capacity for capex or acquisitions, and supports continuity of regulated manufacturing operations through industry cycles and funding shocks.
Negative Factors
Persistent negative free cash flow and uneven cash conversion
Sustained negative free cash flow despite positive operating cash highlights that capex or working-capital needs are absorbing cash. Over months, this reduces internal funding for growth, increases reliance on external financing, and raises execution risk for capacity expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservatively financed balance sheet
Extremely low leverage and a growing equity base provide durable financial resilience. Low debt reduces interest burden, preserves borrowing capacity for capex or acquisitions, and supports continuity of regulated manufacturing operations through industry cycles and funding shocks.
Read all positive factors
Bachem Holding AG (BANB) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF5.59B
Dividend Yield1.21%
Average Volume (3M)109.83K
Price to Earnings (P/E)37.4
Beta (1Y)0.85
Revenue Growth4.51%
EPS Growth11.05%
CountryCH
Employees2,511
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)1.99
Shares Outstanding75,000,000
10 Day Avg. Volume97,857
30 Day Avg. Volume109,830
Financial Highlights & Ratios
PEG Ratio1.27
Price to Book (P/B)3.08
Price to Sales (P/S)6.46
P/FCF Ratio-93.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF77.50Price Target Upside3.26% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)2.37
Revenue Forecast (FY)CHF946.05M
Bachem Holding AG Business Overview & Revenue Model
Company Description
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support fo...
How the Company Makes Money
Bachem makes money primarily by manufacturing and supplying peptide- and oligonucleotide-related products and services to pharma and biotech customers. A core revenue stream is contract development and manufacturing (CDMO): customers pay Bachem fo...
Bachem Holding AG Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 708.53M | 695.07M | 605.26M | 577.32M | 531.74M | 503.23M |
| Gross Profit | 191.33M | 199.73M | 182.56M | 176.96M | 171.28M | 166.73M |
| EBITDA | 189.55M | 189.88M | 178.76M | 163.28M | 160.54M | 156.47M |
| Net Income | 148.96M | 148.79M | 120.25M | 111.86M | 100.68M | 114.68M |
Balance Sheet | ||||||
| Total Assets | 2.34B | 2.11B | 1.92B | 1.68B | 1.38B | 1.30B |
| Cash, Cash Equivalents and Short-Term Investments | 51.57M | 30.99M | 95.20M | 298.53M | 268.43M | 442.36M |
| Total Debt | 208.10M | 57.39M | 290.00K | 401.00K | 691.00K | 20.86M |
| Total Liabilities | 895.36M | 650.41M | 531.88M | 362.36M | 214.21M | 177.50M |
| Stockholders Equity | 1.44B | 1.46B | 1.39B | 1.32B | 1.17B | 1.12B |
Cash Flow | ||||||
| Free Cash Flow | -47.40M | -48.20M | -138.30M | -18.54M | -49.76M | -19.66M |
| Operating Cash Flow | 289.92M | 271.36M | 146.32M | 249.86M | 92.59M | 97.16M |
| Investing Cash Flow | -344.43M | -325.22M | -148.88M | -170.81M | -63.17M | -469.13M |
| Financing Cash Flow | 76.87M | -9.52M | -61.26M | 48.69M | -86.93M | 437.58M |
Bachem Holding AG Technical Analysis
Positive
75.05
Price Trends
72.17
Positive
71.31
Positive
64.74
Positive
Market Momentum
0.25
Positive
52.29
Neutral
39.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BANB, the sentiment is Positive. The current price of 75.05 is above the 20-day moving average (MA) of 74.04, above the 50-day MA of 72.17, and above the 200-day MA of 64.74, indicating a bullish trend. The MACD of 0.25 indicates Positive momentum. The RSI at 52.29 is Neutral, neither overbought nor oversold. The STOCH value of 39.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:BANB.
Bachem Holding AG Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | CHF5.25B | 25.13 | 28.54% | 1.15% | -2.39% | 154.37% | |
70 Outperform | CHF3.55B | 20.39 | 15.68% | 0.57% | 2.57% | 4.31% | |
67 Neutral | CHF5.59B | 37.44 | 10.56% | 1.20% | 4.51% | 11.05% | |
66 Neutral | CHF39.50B | -373.64 | ― | 0.91% | -10.77% | -114.77% | |
66 Neutral | CHF4.10B | 25.58 | ― | 2.88% | 6.48% | -17.25% | |
56 Neutral | CHF1.45B | -73.34 | ― | ― | 13.85% | -7.03% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
CH:BANB
Bachem Holding AG
74.60
7.37
10.96%
CH:LONN
Lonza Group Ltd
575.40
35.07
6.49%
CH:SFZN
Siegfried Holding AG
78.50
-9.15
-10.44%
CH:YPSN
Ypsomed Holding AG
409.80
25.55
6.65%
CH:PPGN
PolyPeptide Group AG
43.95
19.75
81.61%
CH:GALE
Galenica AG
81.60
-1.43
-1.72%
Bachem Holding AG Corporate Events
Bachem boosts sales, ramps up capacity for peptide and oligonucleotide growth
Jul 30, 2026
Bachem Holding AG reported first-half 2026 sales of CHF 326.4 million, up 4.3% year-on-year, while EBITDA declined 9% as ramp-up costs for its new large-volume Building K facility weighed on margins. The company saw strong growth in clinical activ...
Bachem to Invest Over CHF 500 Million in New Sisslerfeld Peptide Plant
Jul 21, 2026
Bachem Holding AG plans a major capacity expansion with a new large‑volume peptide production facility at its greenfield site in Sisslerfeld, Eiken, Switzerland, backed by a strategic long‑term supply agreement. The company will invest...
Bachem Plans Hybrid Capital Markets Day in Zurich for 2026
Jun 12, 2026
Bachem Holding AG has scheduled a Capital Markets Day for November 26, 2026, to be held as a hybrid event at The Circle Convention Center at Zurich Airport and online. The company plans to use the event to present its strategic priorities, busines...
Bachem CEO Assumes Dual Role as CCO Departs
May 5, 2026
Bachem has announced that Chief Commercial Officer Torsten Wöhr will leave the company to pursue a new professional opportunity, prompting a reshuffle at the top of the organization. Effective May 25, 2026, CEO Anne‑Kathrin Stoller will...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.